Exclusive Summary

• Significant formulation advantage: Orally Dispersible Tablets (ODT) prevent 'cheeking' and resolve dysphagia in psychiatric patients, dramatically improving treatment adherence.
• Definite clinical necessity: Clozapine is the internationally recognized gold standard for Treatment-Resistant Schizophrenia, and the 25mg dose is essential for mandatory initial dosage titration.
• Long-term stable demand: With approximately 7 million TRS patients globally requiring lifelong medication, the product guarantees continuous replenishment and stable distribution revenue.
• Differentiated competition and cost-effectiveness: ODT formulations have higher technical barriers and less competition than regular tablets; coupled with Chinese manufacturing cost efficiency, it strongly empowers clients to win public tenders.